These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Maehara S; Yuge N; Higashi C; Ota T; Furukawa J; Takeuchi T Neuropsychopharmacol Rep; 2020 Jun; 40(2):182-189. PubMed ID: 32337858 [TBL] [Abstract][Full Text] [Related]
18. Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist. Suzuki R; Nozawa D; Futamura A; Nishikawa-Shimono R; Abe M; Hattori N; Ohta H; Araki Y; Kambe D; Ohmichi M; Tokura S; Aoki T; Ohtake N; Kawamoto H Bioorg Med Chem; 2015 Mar; 23(6):1260-75. PubMed ID: 25693785 [TBL] [Abstract][Full Text] [Related]
19. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. Yoshida Y; Naoe Y; Terauchi T; Ozaki F; Doko T; Takemura A; Tanaka T; Sorimachi K; Beuckmann CT; Suzuki M; Ueno T; Ozaki S; Yonaga M J Med Chem; 2015 Jun; 58(11):4648-64. PubMed ID: 25953512 [TBL] [Abstract][Full Text] [Related]
20. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]